INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Na Qu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Epithelial-Mesenchymal Transition, Lapatinib. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) tends to metastasize and has a bad prognosis due to its high malignancy and rapid progression. Inositol polyphosphate 4-phosphatase isoenzymes type II (INPP4B) plays unequal roles in the development of various cancers. However, the function of INPP4B in HER2+ BC has not been elucidated. Here we found that INPP4B expression was significantly lower in HER2+ BC and positively correlated with the prognosis by bioinformatics and tissue immunofluorescence analyses. Overexpression of INPP4B inhibited cell proliferation, migration, and growth of xenografts in HER2+ BC cells. Conversely, depletion of INPP4B reversed these effects and activated the PDK1/AKT and Wnt/β-catenin signaling pathways to promote epithelial-mesenchymal transition (EMT) progression. Moreover, INPP4B overexpression blocked epidermal growth factor (EGF) -induced cell proliferation, migration and EMT progression, whereas INPP4B depletion antagonized HER2 depletion in reduction of cell proliferation and migration of HER2+ BC cells. Additionally, Lapatinib (LAP) inhibited HER2+ BC cell survival, proliferation and migration, and its effect was further enhanced by overexpression of INPP4B. In summary, our results illustrate that INPP4B suppresses HER2+ BC growth, migration and EMT, and its expression level affects patient outcome, further providing new insights into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory…
- Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: pengyangpoop6@qq.com.
Zitieren
APA
Qu, N., Wang, G., Su, Y., Chen, B., Zhou, D., Wu, Y., Yuan, L., Yin, M., Liu, M., Peng, Y., & Zhou, W. (2024). INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116347
Vancouver
Qu N, Wang G, Su Y, Chen B, Zhou D, Wu Y, et al. INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116347
BibTeX
@article{Qu2024,
author = {Qu, Na and Wang, Gang and Su, Yue and Chen, Bo and Zhou, Duanfang and Wu, Yuanli and Yuan, Lie and Yin, Manjialan and Liu, Mingpu and Peng, Yang and Zhou, Weiying},
title = {INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116347}
}
EUVIMED